Edition:
United Kingdom

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

5.20USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$5.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
43,954
52-wk High
$8.80
52-wk Low
$3.72

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $123.10
Shares Outstanding(Mil.): 16.86
Dividend: --
Yield (%): --

Financials

  CDTX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -3.55 -- --
ROI: -72.93 2.00 14.38
ROE: -77.58 3.49 16.08

BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln

* CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS

21 May 2018

BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin

* CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN

21 Mar 2018

BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin

* CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN

19 Mar 2018

BRIEF-Cidara Posts Q4 Loss Per Share $0.69​

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

Earnings vs. Estimates